Phibro Animal Health CORP

Phibro Animal Health Corporation announced the declaration of its quarterly cash dividend of $0.12 per share for both Class A and Class B common stock.

Phibro Animal Health Corporation has appointed Daniel Bendheim as CEO and President, effective July 1, 2026, with a performance-based compensation package.

Phibro Animal Health Corporation announced robust third quarter results with a 10% increase in net sales and a 15% rise in net income, leading to an upward revision of its full fiscal year 2026 financial guidance.

Phibro Animal Health Corporation announced the declaration of a quarterly cash dividend of $0.12 per share on its common stock.

Phibro Animal Health Corporation announced a new Brazilian regulatory framework for antimicrobials, expecting limited impact on fiscal 2026 results.

Phibro Animal Health Corporation announces the upcoming resignation of Director Joyce J. Lee, effective April 15, 2026, citing no disagreements with the company.

Phibro Animal Health Corporation announced a 10% increase in net sales for the third quarter of fiscal year 2026, driven by robust performance in its Animal Health segment.

Phibro Animal Health Corporation reported significantly increased net sales and net income for the quarter and six months ended December 31, 2025, driven by the Zoetis acquisition and organic growth.

Phibro Animal Health Corporation reported a 40% surge in net sales and a significant increase in net income for the quarter ended September 30, 2025, largely driven by its recent Zoetis acquisition and strong Animal Health segment growth.

Phibro Animal Health Corporation reports a significant increase in net sales and operating income for Q3 2025, primarily driven by the acquisition of Zoetis' medicated feed additive portfolio and overall sales growth.

Phibro Animal Health Corporation reports a significant increase in net sales and operating income for the second quarter of fiscal year 2025, primarily driven by the acquisition of Zoetis's medicated feed additive portfolio and increased demand across its segments.

Phibro Animal Health Corporation reported a significant increase in net income for the quarter ended September 30, 2024, driven by strong sales growth and improved gross margins.

Phibro Animal Health Corporation announced significant revenue and profit increases for fiscal year 2025, largely propelled by its strategic acquisition of Zoetis's medicated feed additive portfolio.

Phibro Animal Health Corporation's 10-K filing details its financial performance for fiscal year 2024, highlighting growth in animal health and strategic moves amidst industry challenges.

Patrick Rodriguez, VP Finance and Treasurer of Phibro Animal Health Corp, received 1,503 shares of common stock on August 6, 2026.

Glenn David, Chief Financial Officer of Phibro Animal Health Corp, received 3,334 shares of common stock on August 6, 2026.

Larry Lee Miller, Chief Operating Officer of Phibro Animal Health Corp, received 3,522 shares of common stock on August 6, 2026.

Jonathan Bendheim, a Director of Phibro Animal Health Corp, received 2,716 shares of common stock on August 6, 2026.

Judith Weinstein, See Remarks of Phibro Animal Health Corp, received 2,478 shares of common stock on August 6, 2026.

Jack Bendheim and 1 other reported changes in beneficial ownership of Phibro Animal Health Corp common stock on August 6, 2026.

Phibro Animal Health Corporation announces its 2025 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation, and auditor ratification.

Phibro Animal Health Corporation announces its 2025 Annual Meeting agenda, highlighting strong fiscal year 2025 financial performance and executive compensation details.

Phibro Animal Health Corporation will hold its 2024 Annual Meeting of Stockholders on November 5, 2024, to vote on the election of directors and the ratification of the company's independent auditor.

Phibro Animal Health Corporation will hold its 2024 Annual Meeting of Stockholders on November 5, 2024, to elect directors and ratify the selection of its independent accounting firm.

BFI Co., LLC and Jack C. Bendheim have established a Rule 10b5-1 trading plan to sell up to 750,000 shares of Phibro Animal Health Class A Common Stock.

BFI Co., LLC and Jack C. Bendheim disclosed a series of market sales of Phibro Animal Health Class A Common Stock.

BFI Co., LLC, controlled by Jack C. Bendheim, has adopted a Rule 10b5-1 sales plan to sell up to 528,000 shares of Phibro Animal Health Class A Common Stock for diversification.

BFI Co., LLC, a significant shareholder of Phibro Animal Health Corporation, has adopted a Rule 10b5-1 sales plan to sell up to 528,000 shares of Class A Common Stock for diversification purposes.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 15.0% of Phibro Animal Health Corp's Class A Common Stock as of June 30, 2026.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 5.1% of Phibro Animal Health Corporation's Class A Common Stock.

Barclays PLC has filed a Schedule 13G disclosing a 1.27% beneficial ownership stake in Phibro Animal Health Corp.

Vanguard Capital Management has reported beneficial ownership of 5.06% of Phibro Animal Health Corp.'s common stock as of March 31, 2026.

FMR LLC, along with Abigail P. Johnson, has reported beneficial ownership of 2,173,126.20 shares, representing 10.5% of Phibro Animal Health Corp's Class A Common Stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Phibro Animal Health Corp common stock following an internal realignment.